Deliberate Release and Placing on the EU Market of GMOs - GMO Register
Legal Notice   Privacy statement   English (EN)
   European Commission > EU Science Hub > GMOinfo - GMOregister
Home
Image  

Deliberate release into the environment of other than plants GMOs for any other purposes than placing on the market (experimental releases)

List of SNIFs submitted to the Member State's Competent Authorities under Directive 2001/18/EC (after 17 October 2002)

Click here for an historic overview of all data since 1991e 1991

 
Notification NumberMember StatePublicationName of the Institutes or CompaniesProject titleFinal report
B/BE/16/BVW1Belgium29/11/2016Amgen Limited, UKA Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors 
B/DE/16/PEI2698Germany29/11/2016NightstaRx LtdA Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) 
B/DE/16/PEI2797Germany29/11/2016Royal Holloway and Bedford New College, University of LondonSafety and immunogenicity study of a Clostridium difficile vaccine in healthy adult volunteers 
B/IT/16/02Italy29/11/2016University of Pennsylvania (UPenn)AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH). 
B/NL/15/013Netherlands29/11/2016Aanofi-Aventis GroupeGene therapy Clinical development program comprising of clinical trials using SAR422459, a non-replicating, recombinant lentiviral vector derived from Equine Infectious Anemia Virus (EIAV) to express ATP Binding Cassette A4 (ABCA4) transporter and correct its defective expression or function in photoreceptors of patients with Stargardt macular dystrophy and other ABCA4 retinopathies. 
B/NL/16/005Netherlands23/11/2016Erasmus MCTesting the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies. KTE-C19 is a novel adoptive cellular immunotherapy for cancer whereby autologous T cells are genetically modified/transduced ex vivo by a replication-deficient retroviral vector to express anti-CD19 chimeric antigen receptors (CAR) on the surface of T cells to target malignant B cells expressing CD19 antigens. 
B/NL/16/006Netherlands23/11/2016Princess Maxima Center for Pediatric OncologyTesting the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies. KTE-C19 is a novel adoptive cellular immunotherapy for cancer whereby autologous T cells are genetically modified/transduced ex vivo by a replication-deficient retroviral vector to express anti-CD19 chimeric antigen receptors (CAR) on the surface of T cells to target malignant B cells expressing CD19 antigens. 
B/NL/16/007Netherlands23/11/2016University Medical Center GroningenTesting the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies. KTE-C19 is a novel adoptive cellular immunotherapy for cancer whereby autologous T cells are genetically modified/transduced ex vivo by a replication-deficient retroviral vector to express anti-CD19 chimeric antigen receptors (CAR) on the surface of T cells to target malignant B cells expressing CD19 antigens. 
B/NL/16/003Netherlands23/11/2016University Medical Center UtrechtTesting the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies. KTE-C19 is a novel adoptive cellular immunotherapy for cancer whereby autologous T cells are genetically modified/transduced ex vivo by a replication-deficient retroviral vector to express anti-CD19 chimeric antigen receptors (CAR) on the surface of T cells to target malignant B cells expressing CD19 antigens. 
B/NL/16/004Netherlands22/11/2016Academic Medical CenterTesting the safety and efficacy of KTE-C19 in patients with refractory or relapsed B-cell malignancies. KTE-C19 is a novel adoptive cellular immunotherapy for cancer whereby autologous T cells are genetically modified/transduced ex vivo by a replication-deficient retroviral vector to express anti-CD19 chimeric antigen receptors (CAR) on the surface of T cells to target malignant B cells expressing CD19 antigens. 
B/ES/16/10Spain22/11/2016CEVA Salud Animal, S.A.Vaccination of chickens with a combination vaccine against infectious LT, FP and AE diseases. 
B/ES/16/11Spain22/11/2016Aelix TherapeuticsA phase I randomized, placebo-controlled trial, to evaluate the safety, tolerability and immunogenicity of experimental HIV-1 vaccines, DNA.HTI and MVA.HTI administered in HIV-1 negative volunteer adults (Aelix-oo1). 
B/ES/16/09Spain16/11/2016Celgene CorporationStudy of JCAR015 in clinical trials with patients with B cell malignancies 
B/NL/16/008Netherlands15/11/2016Erasmus MCSafety and protective efficacy of genetically modified Plasmodium berghei (Pb(PfCS@UIS4)) malaria parasites in healthy volunteers 
B/NL/16/010Netherlands15/11/2016HavenziekenhuisSafety and protective efficacy of genetically modified Plasmodium berghei (Pb(PfCS@UIS4)) malaria parasites in healthy volunteers 
B/DE/16/PEI2680Germany07/11/2016SillaJen Inc.Clinical Study JX594-HEP024, “A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy”. 
B/ES/16/07Spain22/09/2016GlaxoSmithKline BiologicalsA study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in RSVseropositive infants 
B/ES/16/08Spain22/09/2016Dimension Therapeutics, Inc.Clinical Study 301OTC01, “A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)- Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC Deficiency” 
B/PT/16/03Portugal01/08/2016Amgen Limited, UKA Phase 1b/3, Multicenter Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of, Unresectable, Stage IIIB to IVM1c Melanoma (20110265) 
B/IT/16/01Italy01/08/2016University of Pennsylvania (UPenn)AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH). 
B/FR/16/GT02France29/07/2016Centre Léon BérardISI-JX - A Phase I trial evaluating the impact of an in situ Immunization strategy with Intra-Tumoral Injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions 
B/DE/16/PEI2623Germany29/07/2016Amgen Limited, UKA Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (20130232) 
B/DE/16/PEI2572Germany23/06/2016Cell Therapy CatapultA single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) with low blast counts failing to achieve an IWG defined response following azacitidine therapy. 
B/GB/16/R48/01United Kingdom23/06/2016University of Oxford, UKInvestigating the role of typhoid toxin in the pathogenesis of enteric fever: A double-blinded, randomised, outpatient human challenge study. 
B/NL/16/001Netherlands22/06/2016Centre of Human Drug ResearchA single dose clinical trial to study the safety of ART-I02 in patients with Rheumatoid Arthritis 
B/NL/16/002Netherlands22/06/2016Leiden University Medical CenterA single dose clinical trial to study the safety of ART-I02 in patients with Rheumatoid Arthritis 
B/CZ/16/2Czech Republic09/06/2016Nemocnice na HomolceA phase I, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, in men with advanced metastatic castration-resistant prostate cancer 
B/ES/16/05Spain30/05/2016Universidad de NavarraPhase II randomized trial of DNX-2401 oncolytic adenovirus added to standard of care for newly diagnosed glioblastoma 
B/ES/16/06Spain30/05/2016Universidad de NavarraPhase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. 
B/DE/15/PEI2482Germany15/04/2016Novartis Pharma AGA phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 
B/DE/15/PEI2483Germany15/04/2016Novartis Pharma AGLong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell Therapy directed against CD19 
B/DE/15/PEI/2484Germany15/04/2016Novartis Pharma AGA clinical study to determine the efficacy and safety of CTL019, an investigational gene therapy, in children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia 
B/HU/16/01Hungary04/04/2016Ceva Phylaxia Co LtdVaccination of chickens with a combination vaccine against infectious LT, FP and AE diseases 
B/ES/16/04Spain23/03/2016Targovax OyA randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS 102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma 
B/PT/16/01Portugal22/03/2016Amgen Limited, UKA Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (20130232) 
B/DE/16/PEI2504Germany17/03/2016GENSIGHT BiologicsA Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by Leber Hereditary Optic Neuropathy Due to the G11778A Mutation in the Mitochondrial NADH Dehydrogenase 4 Gene 
B/DE/16/PEI2505Germany17/03/2016GENSIGHT BiologicsA Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months and to12 months by Leber Hereditary Optic Neuropathy Due to the G11778A Mutation in the Mitochondrial NADH Dehydrogenase 4 Gene 
B/DE/16/PEI2516Germany12/02/2016VAXIMM GmbHVXM01 phase I pilot study in patients with operable recurrence of a glioblastoma to examine safety, tolerability, immune and biomarker response to the investigational VEGFR-2 DNA vaccine VXM01 (Study Code VXM01-02-DE) 
B/DE/15/PEI2509Germany12/02/2016VAXIMM GmbHVXM01 phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01 
B/DE/15/PEI2422Germany12/02/2016University of TübingenTHOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1) 
B/DE/15/PEI2425Germany12/02/2016apceth GmbH & Co.KGClinical Trial: Treatment of Advanced Gastrointestinal Adenocarcinoma in a Phase I/II trial with modified allogeneic MSC_apceth_111 
B/NL/15/012Netherlands12/02/2016Novartis Pharma AGCTL019 Autologous genetically modified T cells, intravenous infusion Treatment of relapsed/refractory B cell malignancies 
B/ES/16/01Spain19/01/2016Amgen Limited, UKA Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous SystemTumors That are Amenable to Direct Injection 
B/ES/15/15Spain22/12/2015Sant Joan de Déu Research FoundationA phase I, unicentric, open -label and dose escalation clinical study to evaluate the safety and the antitumoral activity of VCN-01 in patients with refractory retinoblastoma 
B/ES/15/08Spain10/12/2015Novartis Pharma AGCTL019 Autologous genetically modified T cells, intravenous infusion Treatment of relapsed/refractory B cell malignancies 
B/FI/15/1MAFinland10/12/2015Docrates SyöpäsairaalaA phase I, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, in men with advanced metastatic castration-resistant prostate cancer 
B/ES/15/14Spain07/12/2015Amgen Limited, UKA Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. (20130232) 
B/BE/15/BVW2Belgium07/12/2015Amgen Limited, UKA Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (20130232) 
B/NL/15/010Netherlands07/12/2015Radboud university medical centerSafety and protective efficacy of genetically modified Plasmodium berghei (Pb(PfCS@UIS4)) malaria parasites in healthy volunteers 
B/NL/15/011Netherlands07/12/2015Intervet International bvVaccination of chickens with a herpes virus of turkey vaccine with inserted the F-gene of Newcastle Disease Virus and the VP2 gene of Infectious Bursal Disease Virus. 
B/ES/15/10Spain04/12/2015Abeona TherapeuticsPhase I/II Gene Therapy Clinical Trial of scAAV9.U1a.SGSH for Mucopolysaccharidosis IIIA 
B/ES/15/11Spain04/12/2015Abeona TherapeuticsPhase I/II Gene Therapy Clinical Trial of rAAV9.CMV.NAGLU for Mucopolysaccharidosis IIIB 
B/ES/15/12Spain04/12/2015IrsiCaixa AIDS Research InstituteAN OPEN LABEL PHASE I TRIAL TO EVALUATE THE SAFETY AND EFFECT OF HIVconsv VACCINES IN COMBINATION WITH HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN ON THE VIRAL REBOUND KINETIC AFTER TREATMENT INTERRUPTION IN EARLY TREATED HIV-1 INFECTED INDIVIDUALS. 
B/ES/15/13Spain04/12/2015MolMed SpATK008: randomized Phase III study of haploidentical HCT with or without an add back strategy of HSV-TK donor lymphocytes in patients with high risk acute leukaemia 
B/SE/14/000614-64Sweden07/10/2015Uppsala UniversityPhase I/IIa Study of recombinant adenovirus in patients with neuroendocrine tumors; safety and efficacy. 
B/DE/15/PEI2337Germany05/10/2015University of TübingenSafety and efficacy of a single subretinal injection of rAAV.hCNGA3 in patients with CNGA3-linked achromatopsia investigated in an exploratory, dose-escalation trial 
B/ES/15/09Spain01/09/2015Cristina Alzina Fernandez-Figares Merck Sharp & Dohme de España S.APhase III clinical trial, randomized, placebo-controlled study to evaluate the safety and the immunogenicity of three batches of stability and a lot of high doses of rVSV-ZEBOV-GP (vaccine against Ebola virus V920) in healthy adults 
B/NL/15/004Netherlands01/09/2015Leiden University Medical CenterExposure of human test subjects to live genetically attenuated Pf∆b9∆slarp malaria parasites 
B/NL/15/009Netherlands01/09/2015Radboud university medical centerExposure of human test subjects to live genetically attenuated Pf∆b9∆slarp malaria parasites 
B/ES/15/07Spain10/08/2015Amgen Limited, UKA Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors (20140318) 
B/DE/15/PEI2260Germany10/08/2015Transgene S.A.A phase I/IB randomized, double-blind, placebo controlled dose finding study to evaluate the safety, tolerability, and immune response of single and multiple dose of the hepatitis B specific replication-defective adenovirus serotype 5 (Ad5) vector based vaccine, TG1050, and an initial evaluation of immunologic and antiviral activity in the treatment of patients with chronic hepatitis B infection 
B/DE/14/2247Germany10/08/2015Universitätsklinikum Hamburg-EppendorfPhase I clinical testing of experimental Ebola Vaccine VSVΔG-ZEBOV 
B/DE/14/PEI2133Germany10/08/2015Amgen Limited, UKA Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresected, Stage IIIb-IV Melanoma 
B/DE/14/PEI2170Germany10/08/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/DE/14/PEI2194Germany10/08/2015Amgen Limited, UKA Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec 
B/BE/15/BVW1Belgium10/08/2015Amgen Limited, UKA Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma (20110265) 
B/DE/12/1750Germany10/08/2015apceth GmbH & Co.KGClinical Study: Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous mesenchymal cells MSC_apceth_101 
B/ES/15/06Spain20/07/2015Oxitec Ltd.Evaluation of the mating competitiveness, longevity and persistance of the OX3097D-Bol olive fly in a field setting 
B/NL/15/002Netherlands20/07/2015University Medical Center UtrechtThe AGM0001Study: A phase 3 double-blind, randomized, placebo- controlled study to evaluate the safety and efficacy of AGM0001 in subjects with critical limb ischemia. 
B/NL/15/003Netherlands20/07/2015Stichting Het Nederlands Kanker InstituutIntradermal vaccination with naked DNA, encoding the fusion protein of a carrier sequence sig-HELP-kdel and the shuffled version of the Human papilloma virus (HPV) E6 or E7 oncoprotein for the induction of E6 and E7 specific T cell immunity in patients with HPV induced (pre-)malignancies. 
B/NL/15/008Netherlands29/06/2015Academisch Ziekenhuis MaastrichtThe AGM0001Study: A phase 3 double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of AGM0001 in subjects with critical limb ischemia. 
B/NL/14/006Netherlands29/06/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/NL/14/007Netherlands29/06/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/NL/14/008Netherlands29/06/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/NL/15/001Netherlands29/06/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/HU/15/01Hungary29/06/2015Transgene S.A.The project, TG4010.14 clinical trial, is entitled “A Phase IIb/III randomized, double blind, placebo controlled, study comparing first line therapy with or without the therapeutic vaccine TG4010 in patients with stage IV non small cell lung cancer (NSCLC) 
B/FR/15/GT05France18/05/2015GENETHONA phase I/II, non-randomized, monocentric, open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-Linked Chronic Granulomatous Disease 
B/FR/15/GT06France18/05/2015Amgen Limited, UKA Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec 
B/FR/15/GT07France18/05/2015Amgen Limited, UKA phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma 
B/ES/15/04Spain30/04/2015Amgen Limited, UKA Phase 3b, Multicentre, Single-arm, expanded Access Protocol of Talimogene Laherparepvec for the treatment of Subjects in Europe with Unresected Stage IIIB to IVM1c Melanoma. (20120328) 
B/FR/15/GT03France01/04/2015Institut BergoniéThe clinical study to be conducted with JX-594 is entitled: “A phase Ib/II study of metronomic cyclophosphamide and the oncolytic poxvirus JX-594 in patients with advanced breast cancer and advanced soft tissue sarcoma”. The clinical study short title is METROmaJX. 
B/FR/15/GT04France27/03/2015Bluebird bio, IncClinical trial ALD-102 titled: “A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti-D lentiviral vector for the treatment of childhood cerebral adrenoleukodystrophy (CCALD)”. 
B/FR/15/GT01France25/03/2015Amgen Limited, UKA Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab ompared to Ipilimumab Alone in Subjects With Previously Untreated, Unresected, Stage IIIb-IV Melanoma 
B/FR/15/GT02France25/03/2015Transgene S.A.A phase I/IB randomized, double-blind, placebo controlled dose finding study to evaluate the safety, tolerability, and immune response of single and multiple dose of the hepatitis B specific replication-defective adenovirus serotype 5 (Ad5) vector based vaccine, TG1050, and an initial evaluation of immunologic and antiviral activity in the treatment of patients with chronic hepatitis B infection 
B/GB/15/R47/01/NIUnited Kingdom12/02/2015Prokarium Ltd.Development of a Combination Vaccine Against Typhoid Fever and Enterotoxigenic Escherichia Coli (ETEC): A Phase 1, Single Centre, Randomised, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Oral Live Attenuated Vaccine based on the “Vaxonella” platform technology (Typhetec) at three ascending dose levels 
B/SE/15/EU-2013-005579-42Sweden12/02/2015uniQure Biopharma B.V.An open-label, uncontrolled, single-dose, dose-escalation, multi-centre trial investigating the safety and efficacy of systemic administration of AAV5-hFIX, an adeno-associated viral vector containing a codon-optimised human factor IX gene, to severe haemophilia B 
B/HU/14/01Hungary16/12/2014Amgen Limited, UKA Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec 
B/ES/14/07Spain15/12/2014Instituto Valenciano de Investigaciones Agrarias (IVIA)Reduction of the period for citrus flowering by the use of a viral vector based on Citrus leaf blotch virus 
B/ES/14/08Spain19/11/2014Amgen Limited, UKA Phase 2, Multicenter, Randomized, Openlabel Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma (20110266) 
B/ES/14/09Spain19/11/2014Laboratorios del Dr. Esteve, S.A.Phase I/II safety, tolerability and initial efficacy study of adenoassociated viral vector serotype 9 containing human Sulfamidase gene after intracerebroventricular administration to patients with Mucolopolysaccharidosis IIIA (Sanfilippo A syndrome). 
B/SI/14/01Slovenia19/11/2014University of LjubljanaThe combination of surgery or electrochemotherapy and gene electrotransfer of naked plasmid DNA encoding canine interleukin 12 for the treatment of oral and skin tumors in dogs 
B/BE/14/BVW1Belgium01/10/2014Amgen Limited, UKA Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec 
B/ES/14/05Spain29/08/2014Amgen Limited, UKA Phase 2, Multicenter, Open-label, Singlearm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec (20120325) 
B/ES/14/06Spain29/08/2014Amgen Limited, UKA Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma (20110265) 
B/SE/14/EU-2014-000185-22Sweden07/08/2014Amgen Limited, UKA Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma (20110265) 
B/ES/13/21Spain09/07/2014Laboratorios Hipra, S.A.Assessment of the safety and efficacy of the live vaccine PB-35 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae 
B/IE/14/01Ireland02/05/2014St. James’s Hospital(a) A Phase 1 study to assess the safety and immunogenicity of AdCh3NSmut1 and MVA-NSmut in HIV-1 seropositive HCV-uninfected adults on ART 
B/IE/14/02Ireland02/05/2014St. James’s HospitalA Phase I study to assess the safety and immunogenicity of prime-boost immunisations with vaccine candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 seropositive HCV-uninfected adults on antiretroviral therapy (ART) 
B/FR/13/GT07France18/12/2013Centre Hospitalier Universitaire de BesançonUse of genetically modified T-lymphocytes expressing the inducible human caspase 9 gene (iCASP9) and the selection gene ΔCD19 for the treatment of Graft versus Host Disease (GvHD) in allogeneic haematopoietic transplantation: Study Side by Cide 
B/ES/13/22Spain18/12/2013CEVA Salud Animal, S.A.Vaccination of chickens with a combination vaccine against infectious LT and FP disease. 
B/DE/13/PEI1863Germany02/12/2013GENETHONPhase I/II Clinical Study of autologous CD34+ cells transduced ex vivo with the G1XCGD lentiviral vector containing the GP91 transgene which is a codon-optimized cDNA of the human CYBB gene (also known as GP91-PHOX gene) for the Treatment of X-linked chronic granulomatous disease (G1XCGD). 
B/FR/13/GT06France22/10/2013Astellas PharmaA Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (Study 0113-CL-1004) 
B/FR/13/GT04France02/10/2013Oxford BioMedica UK Ltd.A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected UshStat® Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B (US1/001/10) 
B/FR/13/GT05France27/08/2013GENETHONA phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-CMV-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene 
B/ES/13/07Spain30/07/2013Oxitec Ltd.Evaluation of the mating competitiveness, longevity and persistence of the OX3097D‐Bol Olive fly in a field setting. 
B/FR/13/GT03France18/06/2013Institut national de la santé et de la recherche médicalePhase I/II open-label randomized multicenter trial to assess immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVA HIV-B/LIPO-5; LIPO-5/MVA HIV-B; GTU-MultiHIV B/LIPO-5; GTU-MultiHIV B/MVA HIV-B) in healthy volunteers at low risk of HIV infection (ANRS VRI01) 
B/HU/13/01Hungary18/06/2013Celladon CorporationA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure. 
B/DE/13/PEI1827Germany07/06/2013BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 
B/NL/12/004Netherlands17/05/2013University Medical Center GroningenA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (CUPID Phase 2b Trial) 
B/NL/12/006Netherlands07/05/2013Academic Medical Center Amsterdam, the NetherlandsA phase 2b, double-blind, placebo-controlled, multinational, multicenter, randomized study evaluating the safety and efficacy of intracoronary administration of MYDICAR® (AAV1/SERCA2a) in subjects with heart failure (CUPID phase 2b trial) 
B/FR/13/GT01France07/05/2013Assistance Publique Hôpitaux de ParisEtude du transfert de gène Serca2a via un vecteur de type AAV 1 (adéno-associated viral 1) pour le traitement de l’insuffisance cardiaque sévère: une étude pilote 
B/FR/13/GT02France07/05/2013Institut PasteurA phase I/II, open‐label, study of intracerebral administration of adeno‐associated viral vector containing the human alpha‐N‐acetylglucosaminidase gene for the treatment of Sanfilippo type B syndrome 
B/NL/12/005Netherlands18/04/2013University Medical Center UtrechtA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (CUPID Phase 2b Trial) 
B/NL/13/002Netherlands05/04/2013Stichting Het Nederlands Kanker InstituutIntradermal vaccination with naked DNA, TTFC-E7SH, encoding the fusion protein domain1 of tetanus toxin fragment C and the shuffled version of the Human papilloma virus (HPV) E7 oncoprotein for the induction of E7 specific T cell immunity in stage IV squamous cell cancer patients 
B/ES/13/18Spain05/04/2013Clínica Universidad de NavarraPhase I Clinical Trial of Delta-24-RGD oncolytic adenovirus and temozolomide for treatment of glioblastoma at first recurrence 
B/IE/13/01Ireland04/03/2013Children’s Hospital of PhiladelphiaA Phase 1 safety study in subjects with severe Hemophilia B (Factor IX deficiency) using a single-stranded, adeno-associated pseudotype 8 viral vector to deliver the gene for human Factor IX [Protocol # AAV8-hFIX19-101] 
B/GB/13/R46/01United Kingdom13/02/2013Celladon CorporationA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure and Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device 
B/GB/13/R46/01/SUnited Kingdom13/02/2013Celladon CorporationA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure and Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device 
B/DE/12/PEI1713Germany13/02/2013JW Goethe UniversityA Phase I-II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector 
B/IE/12/02Ireland31/01/2013Intervet International bvA blinded, placebo controlled, clinical and efficacy study of Equilis RhodE in horses in Ireland
B/DE/12/PEI1667Germany10/01/2013Celladon CorporationPlacebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (CUPID Phase 2b Trial) 
B/DE/10/PEI1279Germany10/01/2013MolMed SpATK008: Randomized phase III trial of haploidentical HCTwith or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia 
B/DE/11/PEI1393Germany10/01/2013VAXIMM GmbHVXM01 phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 
B/ES/13/04Spain10/01/2013VCN Biosciences S.L.A phase I, multicenter, open‐label, dose escalation study of intravenous administration of VCN‐01 oncolytic adenovirus alone and in combination with intravenous gemcitabine in patients with advanced solid tumors 
B/ES/13/05Spain10/01/2013VCN Biosciences S.L.A phase I, multi‐center, open‐label, dose escalation study of intratumoral injection of VCN‐01 oncolytic adenovirus in combination with intravenous gemcitabine in advanced pancreatic cancer 
B/BE/12/BVW2Belgium21/12/2012Celladon CorporationA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (CUPID Phase 2b Trial) 
B/DE/11/PEI1419Germany07/12/2012Transgene S.A.The project, TG4010.14 clinical trial, is entitled “A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)” 
B/DE/11/PEI1491Germany07/12/2012Transgene S.A.The project, JX594-HEP018 clinical trial, is entitled “A Phase 2b Randomized, Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment (JX594-HEP018)” 
B/DE/11/PEI1332Germany07/12/2012Transgene S.A.The project, CVC-MP-TG4040-01 clinical trial, is entitled “Open-label, phase I study combining prime injections of ChronVac-C (DNA-HCV) electroporated with MedPulser DNA delivery system (MedPulser DSS) with boost injections of TG4040 (MVA-HCV) in treatment-naïve subjects chronically infected with hepatitis C virus (HCV genotype 1)”. 
B/FR/12/GT06France07/12/2012Transgene S.A.The project, JX594-CRC019 clinical trial, is entitled “A Phase 1/2a Dose-Escalation Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Followed by Intratumoral (IT) Boosts Alone and in Combination with Irinotecan in Patients with Metastatic, Refractory Colorectal Carcinoma” 
B/SE/12/EU-2012-001700-37Sweden20/11/2012Celladon CorporationA Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects with Heart Failure (CUPID Phase 2b Trial) 
B/NL/12/002Netherlands19/11/2012Oncolytic adenovirus therapy using a prostate-specific conditionally replication-competent adenovirus as an adjuvant treatment for localised prostate cancer 
B/NL/11/006Netherlands19/11/2012Intervet International bvVaccination of chickens with a combination vaccine against infectious laryngotracheitis (ILT) and Marek’s disease (MD) 
B/GB/12/R44/01/NIUnited Kingdom14/11/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” 
B/FR/12/GT05France29/10/2012Transgene S.A.A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients with Advanced Hepatocellular Carcinoma (HCC). 
B/ES/12/37Spain08/10/2012Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT)Clinical Trial Phase I / II study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells mobilized with Filgrastim and Mozobil and transduced with a lentiviral vector carrying the FANCA gene (Orphan drug) for patients with Fanconi anemia subtype A 
B/FR/12/GT04France04/10/2012Bluebird bio, IncClinical trial HGB-205 titled: "A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the  Hemoglobinopathies (Sickle Cell Anemia and " Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with a Lentiviral "A-T87Q Globin Vector (LentiGlobin® BB305 Drug Product)". 
B/GB/12/R44/01/SUnited Kingdom04/10/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” 
B/GB/12/R45/01United Kingdom04/10/2012International AIDS Vaccine Initiative, New York, USAA Phase I double-blind, randomized, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a Sendai HIV vaccine SeV-G(NP) given intra-nasally and Ad35-GRIN administered intramuscularly in prime-boost regimens in HIV-uninfected, healthy adults volunteers. 
B/GB/12/R44/01United Kingdom04/10/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” 
B/HU/12/01Hungary24/09/2012Ceva Phylaxia Co LtdField safety and efficacy study for Vectormune ND applied subcutaneously or in ovo to broiler chickens. 
B/FR/12/GT03France21/09/2012InsermA phase I/II, Open Labeled, Monocentric Study of Direct Intracranial Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human ARSA cDNA to Children with Metachromatic Leukodystrophy 
B/ES/12/40Spain24/08/2012Transgene S.A.A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients with Advanced Hepatocellular Carcinoma (HCC). 
B/NL/12/001Netherlands24/08/2012Erasmus MCMVA-based recombinant influenza vaccines encoding influenza virus hemagglutinins 
B/ES/12/39Spain05/07/2012Transgene S.A.A Phase 1/2a Dose-Escalation Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Multiple Intravenous (IV) Infusions Followed by Intratumoral (IT) Boosts Alone and in Combination with Irinotecan in Patients with Metastatic, Refractory Colorectal Carcinoma 
B/ES/12/35Spain05/07/2012Digna Biotech SLPhase I, multicentre, open label, single dose, dose-ranging clinical trial to investigate the safety and tolerability of a gene therapy vector rAAV2/5-PBGD for the treatment of Acute Intermittent Porphyria. 
B/ES/12/36Spain05/07/2012VISAVET Health Surveillance Centre“Apoyo técnico científico entre al MARM y el laboratorio comunitario de referencia de la tuberculosis bovina y de eficacia y mejora de las pruebas diagnósticas disponibles” (Technical and scientific support between MARM and the bovine tuberculosis european reference laboratory and improvement of the available diagnostic tools) 
B/FR/12/GT02France15/06/2012THERAVECTYSA multi-center, randomized, double-blind, placebo controlled phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination, at 5.10 10e6 TU, 5.0 10e7 TU or 5.0 10e8 TU doses to placebo in HIV-1 clade B infected patients under highly active antiretrovital therapy (HAART) 
B/FR/12/GT01France06/06/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 
B/BE/12/BVW1Belgium06/06/2012THERAVECTYSA multi‐center, randomized, double‐blind, placebo‐controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5.106 TU, 5.107 TU or 5.108 TU doses to placebo in HIV‐1 clade B infected patients under highly active antiretroviral therapy (HAART) 
B/BE/11/BVW2Belgium06/06/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” 
B/NL/11/002Netherlands10/05/2012University Medical Center GroningenCancer immunotherapy of human papillomavirus-induced (pre)malignant lesion using replication-incompetent Semliki Forest Virus replicon particles encoding human papillomavirus antigens. 
B/NL/10/004Netherlands30/04/2012Intervet International bvNon-pathogenic Mannheimia haemolytica and Pasteurella multocida 
B/IS/12/01Iceland17/04/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer” 
B/EE/12/01Estonia17/02/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" 
B/ES/12/09Spain17/02/2012IrsiCaixa AIDS Research InstituteSafety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART) 
B/ES/12/10Spain17/02/2012IrsiCaixa AIDS Research InstituteSafety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART) 
B/ES/12/11Spain17/02/2012Transgene S.A.The project, JX594-HEP018 clinical trial, is entitled “A Phase 2b Randomized, Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment (JX594-HEP018)”. 
B/ES/12/14Spain17/02/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 
B/ES/12/17Spain17/02/2012FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO INFANTIL NIÑO JESUS“Phase I open Phase I trials to assess efficacy and safety of treatment with autologous mesenchymal cells infected with an oncolitic adenovirus (CELYVIR) in the treatment of paediatric patients with refractory or relapsed solid tumors” 
B/BE/11/V3Belgium08/02/2012Laboratorios Hipra, S.A.Assessment of the safety and efficacy of the live vaccine PB-116 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae 
B/CZ/12/01Czech Republic08/02/2012BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, “A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer 
B/DE/10/213Germany16/01/2012Intervet International bvA non-pathogenic Rhodococcus equi strain as vaccine in horses 
B/GB/11/R44/01United Kingdom25/10/2011BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" 
B/GB/11/R44/01/WUnited Kingdom25/10/2011BN ImmunoTherapeutics, Inc.Clinical Study BNIT-PRV-301, ""A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer" 
B/BE/11/BVW1Belgium17/10/2011Transgene S.A.A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC) 
B/DE/08/PEI706Germany05/10/2011MedImmune, LLCClinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants”. 
B/HU/11/01Hungary27/09/2011Transgene S.A.The project, TG4010.14 clinical trial, is entitled “A Phase IIb/III randomized, double blind, placebo controlled, study comparing first line therapy with or without the therapeutic vaccine TG4010 in patients with stage IV non small cell lung cancer (NSCLC)”. 
B/DE/09/PEI984Germany30/08/2011Mologen AGA Phase 1/2, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Human) Tumor Cells for the Expression of IL-7, GM-CSF, CD80 and CD154, in Fixed Combination with a DNA-based Double Stem Loop Immunomodulator in Patients with Advanced Renal Cell Carcinoma (ASET Study) 
B/DE/10/PEI1035Germany30/08/2011Transgene S.A.A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C 
B/DE/10/PEI1173Germany30/08/2011Genelux GmbHPhase I/II study of intraperitoneal administration of GL-ONC1, a genetically modified vaccinia virus, in patients with peritoneal carcinomatosis 
B/DE/05/PEI35Germany30/08/2011Hesperion LtdA multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of BIOBYPASS® (AdGVVEGF121.10NH) delivered by NOGA™-guided/MYOSTAR™ catheter in “no option” patients with Class II-IV stable angina 
B/DE/06/PEI210Germany30/08/2011Bavarian Nordic GmbHHIV-POL-001: Phase I, Open, Sequential Vaccination Study on Safety and Tolerability of two different doses of recombinant MVA-HIV polytope vaccine (MVA-mBN32) in HIV negative 18-50 year old Healthy Volunteers 
B/DE/06/PEI231Germany30/08/2011Transgene S.A.A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer. 
B/DE/08/PEI574Germany30/08/2011Vakzine Projekt Management GmbHPhase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison with BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination 
B/NL/11/001Netherlands24/08/2011Netherlands Cancer InstituteEx vivo retroviral transduction of human T lymphocytes with melanoma-specific T cell receptor genes 
B/NL/11/003Netherlands24/08/2011Leiden University Medical CenterAdministration of donor specific T-cells transduced ex vivo using a retroviral vector coding for a leukemia-specific TCR, as a cellular treatment after allogeneic stem cell transplantation for patients with refractory or relapsed hematological malignancies. 
B/IE/11/451-AIreland09/08/2011Royal College of Surgeons In IrelandPhase 1 clinical trial to assess the safety and immunogenicity of malaria vaccine
B/IE/11/451-BIreland09/08/2011Royal College of Surgeons In IrelandPhase 1 clinical trial to assess the safety and immunogenicity of malaria vaccine
B/ES/11/28Spain05/07/2011Transgene S.A.A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). 
B/ES/11/27Spain22/06/2011FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO INFANTIL NIÑO JESUSPhase I clinical trial to evaluate ICOVIR5 treatment of paediatric refractory or recurrent tumors of the Central Nervous System 
B/ES/11/25Spain17/05/2011Clínica Universidad de NavarraPhase I-II therapeutic vaccination clinical trial in patients with chronic hepatitis C by administration of autologous dendritic cells transduced with an adenoviral vector encoding NS3 protein 
B/SE/10/EU-2010-023103-94Sweden29/04/2011Uppsala UniversityPhase I/IIa AdCD40L immunogene therapy for malignant melanoma in patients with disseminated disease 
B/GB/10/R40/01United Kingdom23/12/2010Emergent Product Development UK LtdUnderstanding typhoid disease after vaccination: A single centre, randomized, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy volunteer challenge model with the licensed Ty21a vaccine as a positive control 
B/NL/10/002Netherlands24/11/2010Utrecht UniversityVaccination with naked DNA, encoding the xenogenetic human tyrosinase for the induction of specific defence against melanoma cells in dog 
B/NL/09/004Netherlands22/10/2010Intervet International bvA non-pathogenic Rhodococcus equi strain as vaccine in horses. 
B/RO/10/08Romania28/07/2010Parexel International Romania SRLA phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C. 
B/IT/10/01Italy17/06/2010Istituto Zooprofilatico Sperimentale Umbria MarcheImprove tools and strategies for the prevention and the control of classical swine fever
B/IE/10/362Ireland21/05/2010TMC Pharma Services LtdA Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency 
B/SE/10/EU-2010-019936-11Sweden11/05/2010Swedish institute for Infectious Disease ControlInsermKarolinska University HospitalA phase 1, single centre, dose-escalating, placebo-controlled study of a genetically modified B. pertussis strain given as a single intranasal dose to healthy adult male volunteers 
B/NL/10/003Netherlands11/05/2010Leiden University Medical CenterIntradermal vaccination with naked DNA encoding the fusion protein domain1 of tetanus toxin fragment C and MART-1(aa 26-35) for the induction of MART-1-specific T cell immunity in stage IV melanoma patients 
B/ES/10/42Spain01/03/2010Transgene S.A.A phase II randomized, multicenter, openlabel study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 hepatitis C 
B/IT/09/01Italy04/12/2009MerialVaccine candidate against Canine Visceral Leishmaniasis. Evaluation of efficacy by natural challenge in an experimental kennel.
B/NL/08/008Netherlands27/11/2009Erasmus MCA Phase I/II Trial of a Conditionally Replication-Competent Adenovirus (Delta-24-RGD) Administered by Convection Enhanced Delivery in Patients with Recurrent Glioblastoma Multiforme. 
B/NL/08/009Netherlands04/11/2009VU Medical CenterA Phase I/II Trial of a Conditionally Replication-Competent Adenovirus (Delta-24-RGD) Administered by Convection Enhanced Delivery in Patients with Recurrent Glioblastoma Multiforme. 
B/FI/09/1MAFinland26/10/2009MedImmune, LLCMI-CP208, “A Randomized, Double-Blind Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine in Children”. 
B/ES/09/64Spain21/09/2009Institut Català d’Oncologia - IDIBELLPhase I clinical trial of intravenous administration of a conditionally replicating adenovirus ICOVIR-5 in patients with locally advanced or metastasic malignant melanoma. 
B/SE/09/EU-2009-011478-13Sweden15/09/2009Swedish institute for Infectious Disease ControlA phase I trial to assess the safety and feasibility of administering plasmid DNA carrying multiple HIV-1 genes together with dermal electroporation, HIVIS 07 
B/SI/09/01Slovenia31/08/2009University of LjubljanaIntratumoral application of naked DNA, encoding gene for human interleukin 12, followed by electrically-assisted gene transfer into tumor cells of canine patients 
B/GB/09/R43/01United Kingdom15/07/2009MedImmune, LLCClinical Study MI-CP178, "A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants"… 
B/ES/09/63Spain14/05/2009F. Hoffmann-La Roche, Ltd.A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5 x 107 pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection. 
B/BE/09/BVW1Belgium11/05/2009F. Hoffmann-La Roche, Ltd.A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5 x 107 pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infection 
B/NL/08/004Netherlands11/05/2009Leiden University Medical CenterA Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multicenter Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis 
B/ES/09/62Spain21/04/2009Laboratorios Syva, S.A. León (Spain)Efficacy and safety assessment of ISPANVAC vaccine in free-ranging wild rabbits. Location 2. 
B/NL/08/005Netherlands03/04/2009Academic Medical CenterA phase II, double blind randomized study to evaluate the immunogenicity of the therapeutic HIV-1 vaccine NYVAC-B versus placebo in chronic HIV-1 infected patients successfully treated with HAART (TheraVac-03) 
B/FR/08/09/TG01France09/01/2009MedImmune, LLCClinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants”. 
B/GB/08/R43/01/SUnited Kingdom17/12/2008MedImmune, LLCClinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccinelike Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month- Old Children and in 2 Month-Old Infants”. 
B/BE/08/BVW1Belgium27/11/2008MedImmune, LLCClinical Study MI-CP178, A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants. 
B/GB/08/R43/01United Kingdom13/11/2008MedImmune, LLCClinical Study MI-CP178, A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants 
B/NL/08/006Netherlands05/11/2008VumcA randomized double-blind placebo-controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-weeks intervals on amputation or any death in Critical Limb Ischemia patients with skin lesions 
B/FI/08/1MAFinland24/10/2008MedImmune, LLCClinical Study MI-CP178, “A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants”.
B/ES/08/49Spain09/10/2008MedImmune, LLCClinical Study MI-CP178, "A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month-Old Infants". 
B/SE/08/EU-2007-006721-27Sweden26/09/2008Ceregene IncA Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMT-alone in Subjects With Idiopathic Parkinson’s Disease. 
B/ES/08/47Spain16/09/2008Universidad de NavarraA Phase II, Multicenter, Randomized, Controlled, Open-Label Trial to Compare the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) Combined with Best Medical Therapy (BMT) versus BMTalone in Subjects With Idiopathic Parkinson’s Disease. 
B/ES/08/48Spain16/09/2008Laboratorios Hipra, S.A.Assessment of the safety and efficacy of the live vaccine PB-116 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae 
B/ES/08/46Spain09/09/2008Sanofi-Aventis Recherche et DéveloppementA Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax® vs. Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving chemo-based therapy – EFC10528. 
B/NL/08/003Netherlands09/09/2008Stichting Het Nederlands Kanker InstituutIntradermal vaccination with naked DNA encoding the fusion protein domain1 of tetanus toxin fragment C and MART-1(aa 26-35) for the induction of MART-1-specific T cell immunity in stage IV melanoma patients 
B/SE/08/EU-2008-000967-40Sweden03/07/2008ActoGeniX N.V.A Phase 2a Randomized, Placebo-Controlled, Double-Blind, Multicenter Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderately Active Ulcerative Colitis 
B/NL/08/001Netherlands03/07/2008Erasmus MCA randomized double-blind placebo-controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-weeks intervals on amputation or any death in Critical Limb Ischemia patients with skin lesions 
B/ES/07/46Spain03/07/2008Laboratorios Hipra, S.A.Assessment of the safety and efficacy of the live vaccine PB-35 against Porcine Pleuropneumonia caused by Actinobacillus pleuropneumoniae 
B/NL/08/002Netherlands02/07/2008Leiden University Medical CenterA Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® [bicistronic plasmid DNA vector VCL-1005 encoding Human Leukocyte Antigen (HLA)-B7 and β-2 microglobulin, formulated with the cationic lipid delivery system DMRIE-DOPE] Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma 
B/NL/07/011Netherlands02/07/2008University Medical Center GroningenA Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® [bicistronic plasmid DNA vector VCL-1005 encoding Human Leukocyte Antigen (HLA)-B7 and β-2 microglobulin, formulated with the cationic lipid delivery system DMRIE-DOPE] Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma
B/NL/07/010Netherlands10/01/2008Erasmus MC, University Medical Center RotterdamStudy G-0034. A Phase III1 Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain 
B/BE/07/BVW3Belgium10/01/2008GENimmune N.V.A multi-centre phase I study to evaluate the safety and tolerability of a heterologous prime-boost vaccination with INX102-3697 HBV pDNA/INX-102-00557 HBV MVA in healthy volunteers and HBeAg+ chronic hepatitis patients 
B/BE/07/BVW1Belgium05/12/2007ActoGeniX N.V.Phase 1b and Phase 2a clinical trials with an hIL-10-expressing Lactococcus lactis (L. lactis). 
B/ES/07/44Spain13/07/2007Laboratorios Hipra, S.A.Assessment of the safety and efficacy of the live vaccine PB-23 against Infectious Bovine Rhinotracheitis under field conditions 
B/NL/07/03Netherlands07/06/2007Kiwa Water ResearchField test with sensor based on genetically modified bacteria which can detect toxic compounds in water 
B/ES/07/38Spain29/03/2007Laboratorios Syva, S.A. León (Spain)Efficacy and safety assessment of ISPANVAC vaccine in free-ranging wild rabbits. 
B/NL/06/010Netherlands04/12/2006Raboud University Medical CenterStudy G-0029 A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029) 
B/NL/06/011Netherlands04/12/2006AMC AmsterdamStudy G-0034 A Phase III Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain 
B/NL/06/003Netherlands04/12/2006University Hospital MaastrichtStudy G-0029 A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029) 
B/NL/06/009Netherlands27/10/2006Academic Medical CenterAn open-label phase I study to evaluate the safety of the HIV-1 vaccine MVA-B in chronic HIV-1 infected patients successfully treated with HAART 
B/NL/06/001Netherlands08/09/2006Study G-0029 University Medical Center GroningenStudy G-0034 VU Medical CenterA Phase III1 Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naive (G-0029) --- A Phase III1 Randomized, Open-Label Study of Docetaxel in combination with CG1940/CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain (G 0034) 
B/ES/06/42Spain12/07/2006Oxford BioMedica UK Ltd.An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients with locally advanced or metastatic clear cell renal adenocarcinoma. (TV3/001/06) 
B/SE/06/EU-2006-000985-34Sweden15/05/2006Uppsala University, Division of Clinical Immunology, Uppsala.A Phase I-IIa Study of Dose-escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma 
B/NL/05/006Netherlands24/04/2006Erasmus MC, University Medical Center RotterdamAdjuvant IL-12 immuno-gene therapy prior to radical prostatectomy in patients with prostate cancer 
B/ES/06/40Spain29/03/2006Laboratorios Syva, S.A. León (Spain)Safety in pregnant does and duration of immunity assessment of a vaccine based on the virus strain 6918VP60. 
B/FR/06/03/02France16/03/2006Merial LaboratoiresDevelopment of a vaccine against feline rabies. Experiment outside containment (clinical trial) for the study of the safety and the efficacy of a subcutaneous administration of a recombinant canarypoxvirus expressing the surface glycoprotein G gene from Rabies virus (vCP65). 
B/GB/06/R40/01United Kingdom16/03/2006Emergent Europe LtdA double blind, placebo controlled study to evaluate the safety and immunogenicity of escalating doses of a candidate oral immunotherapy (M04NM11, formerly called hepatitis B Candidate 1) in patients who have chronic Hepatitis B infection. 
B/NL/05/02Netherlands09/09/2005Rijksinstituut voor Volksgezondheid en MilieuExploring the health effects due to air pollution by exposure of transgenic mice and rats at location 
B/ES/05/26Spain19/07/2005Laboratorios Syva, S.A. León (Spain)Valoration of effects in rapacious birds and european lynx associated with ingestion of rabbits innoculated with a vaccine based on the strain 6918VP60. 
B/SE/05/151:2005/30190Sweden10/06/2005Swedish institute for Infectious Disease ControlAssessment of the safety and immunogenicity of administering MVA, carrying HIV-1 genes env, gag, and pol in subjects who have previously received plasmid DNA with analogous HIV- 1 genes in HIVIS 01. 
B/NL/05/001Netherlands26/05/2005Academic Medical CenterAdministration of AMT-010, an adenoassociated viral vector (AAV) encoding lipoprotein lipase variant S447X (LPLS447X) to LPL deficient patients 
B/SE/05/KEMI-723-573Sweden25/04/2005Swedish University of Agricultural Sciences - SLURisk assessment of non-resident microorganisms used for biocontrol of fungal pathogens.
B/ES/05/01Spain09/03/2005Consejo Superior de Investigaciones CientíficasField trial of a vaccinie against canine Leishmaniasis 
B/NL/04/001Netherlands29/09/2004Pfizer Animal HealthEvaluation of the safety of a Feline Herpes virus, bivalent gene deleted live vaccine, administered as intranasal vaccination to cats 
B/BE/04/BV1Belgium15/09/2004Pfizer Animal HealthEvaluation of the safety of a Feline Herpes virus, bivalent gene deleted live vaccine, administered as intranasal vaccination to cats 
B/NL/03/08Netherlands04/05/2004VU Medical CenterA phase 1 dose escalation trial of MDX- 010 in combination with CG1940 and CG8711 in patients with metastatic HRPC 
B/NL/03/02Netherlands19/03/2004Erasmus MC, University Medical Center RotterdamArtificial colonization of clumping factor B deficient Staphylococcus aureus in the nose 
B/GB/04/R39/1United Kingdom19/03/2004Natural Environment Research Council (UK)Strategies for risk assessment, evaluating the environmental impact of fungal diseases suppressing GM bacteria on non-target species 
B/BE/03/B3Belgium01/03/2004Transgene S.A.Study TG1024.01: "Phase I multicentre study of TG1024 (Adenovirus interleukin 2) in patients with metastatic melanoma or other advanced solid tumor cancers" 
B/NL/03/05Netherlands19/12/2003International AIDS Vaccine Initiative, New York, USAA double-blind, randomized, placebo controlled dose-escalating phase 1 study to evaluate the safety and immunogenicity of a MVA HIV-1 vaccine administered by three different routes and at three different dosage levels in HIV-uninfected healthy volunteers at lower risk of infection. 
B/NL/03/01Netherlands12/08/2003Academisch Ziekenhuis LeidenGene therapy in aseptic prosthetic replacement loosening. A phase 1 study 
B/ES/03/35Spain23/06/2003Schering Espana SADevelopment of an Angiogenic Gene Therapy Product for Coronary Artery Disease. 
B/GB/03/35/03United Kingdom06/06/2003Acambis Research LtdLive attenuated vaccine for prevention of travellers’ diarrhoea 
B/GB/03/R35/02United Kingdom10/02/2003Acambis Research LtdPhase I clinical trial of a live attenuated Salmonella typhi vaccine for the prevention of typhoid fever 
B/GB/02/37/02United Kingdom10/02/2003Microscience Ltd.An open-label study to determine the safety and immunogenicity of two dose levels (10E8 or 10E9 CFU) of a candidate oral immunotherapy (Hep B Candidate 1) against hepatitis B, given on two occasions, 56 days apart to healthy subjects